Assessment of a drug eluting bioresorbable vascular scafford
    9.
    发明申请
    Assessment of a drug eluting bioresorbable vascular scafford 审中-公开
    评估药物洗脱生物可吸收的血管scafford

    公开(公告)号:US20150073536A1

    公开(公告)日:2015-03-12

    申请号:US14121435

    申请日:2014-09-04

    摘要: A method of treating vascular disease in a patient is disclosed that comprises deploying a bioabsorbable polymer scaffold composed of a plurality of struts at a stenotic segment of an artery of a patient, wherein after the scaffold supports the segment at an increased diameter for a period of time the polymer degrades and is progressively replaced by de novo formation of malleable provisional matrix comprising proteoglycan, wherein as the scaffold becomes more malleable and becomes disconnected as it degrades, wherein following coverage of the struts by a neointima layer and loss of mechanical support provided by the scaffold, the scaffold is pulled outward by positive remodeling of the vessel wall of the scaffolded segment.

    摘要翻译: 公开了一种治疗患者血管疾病的方法,其包括在患者的动脉的狭窄部分部署由多个支柱构成的生物可吸收聚合物支架,其中在所述支架之后以增加的直径支撑所述片段一段时间 聚合物降解的时间逐渐被包含蛋白多糖的可延展的临时基质的从头形成所替代,其中当支架变得更有韧性并且随着其降解而变得断裂,其中由新内膜层覆盖支柱并且由 通过骨架段的血管壁的正重构,支架被向外拉。

    Method Of Treating Vascular Disease In Diabetic Patients
    10.
    发明申请
    Method Of Treating Vascular Disease In Diabetic Patients 有权
    糖尿病患者血管病治疗方法

    公开(公告)号:US20140127278A1

    公开(公告)日:2014-05-08

    申请号:US13668019

    申请日:2012-11-02

    摘要: The present invention relates to the treatment of vascular disease in a diabetic patient using a drug-eluting implantable medical device that releases everolimus from three distinctly loaded drug reservoir layers wherein at least one of the layers comprises at least 200 μg/cm2 of everolimus and further wherein the everolimus is the only therapeutic agent in the layers or the layers or any combination thereof further comprise an anti-inflammatory agent or an RGD peptide or both.

    摘要翻译: 本发明涉及使用药物洗脱可植入医疗装置治疗糖尿病患者的血管疾病,所述药物洗脱可植入医疗装置从三个明显负载的药物储存层释放依维莫司,其中至少一个层包含至少200μg/ cm 2的依维莫司 其中依维莫司是层或层中唯一的治疗剂或其任何组合进一步包含抗炎剂或RGD肽或两者。